A phase II study of carboplatin plus pemetrexed followed by gefitinib for stage IIIB/IV non-small cell lung cancer with EGFR mutatio
Phase 2
- Conditions
- non-small cell lung cancer with EGFR mutation
- Registration Number
- JPRN-UMIN000003354
- Lead Sponsor
- Kanagawa Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who had received chemotherapy or radiotherapy were excluded. Patients who have massive pleural effusion or pericardial effusion, who have uncontrolled cardiac disease, diabetes mellitus or hypertension, who have infectious disease, who have interstitial pneumonitis, were excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year survival rate
- Secondary Outcome Measures
Name Time Method overall survival, progression-free survival, anti-tumor effect, toxicity